Lupin launches generic Fosrenol Chewable Tablets in US

31 Aug 2017 Evaluate

Lupin has launched Lanthanum Carbonate Chewable Tablets 500 mg (base), 750 mg (base), and 1000 mg (base). Lupin’s alliance partner Natco had received an approval from the United States Food and Drug Administration (USFDA) earlier.

Lanthanum Carbonate Chewable Tablets 500 mg (base), 750 mg (base), and 1000 mg (base) are generic equivalents of Shire Development LLC’s Fosrenol Chewable Tablets 500 mg, 750 mg and 1000 mg. Lanthanum Carbonate Chewable Tablets 500 mg (base), 750 mg (base), and 1000 mg (base) are indicated to reduce serum phosphate in patients with end stage renal disease (ESRD). As per IMS MAT June 2017, Fosrenol Chewable Tablets has US sales of $122.4 million.

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.


Lupin Share Price

1647.75 2.30 (0.14%)
02-May-2024 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1520.00
Dr. Reddys Lab 6260.00
Cipla 1419.55
Zydus Lifesciences 988.00
Lupin 1647.75
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.